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ABSTRACT
Phytoestrogens are structurally similar to its mammalian counterparts and are capable of producing estrogen-like effects and non-steroidal in nature. 
Their affinity to bind to the estrogen receptors, a class of cytoplasmic proteins, is far less in comparison to the natural estrogen hormones found in 
humans and other animals or even the synthetically prepared estrogen and, therefore, are far less potent. Even so, the usage of phytoestrogen in either 
dietary or supplemental form in postmenopausal women is gaining interest, as opposed to the conventional estrogen replacement therapy (ERT), 
which was so far being used to alleviate the postmenopausal symptoms and believed, with little experimental/clinical evidence, to cause a significant 
reduction in the threat of coronary heart diseases (CHD). This usage of phytoestrogen follows from the fact that the overall health risks exerted by 
ERT outweigh the benefits, and to a little extent, the perception that synthetically prepared, so-called “prescription estrogen” interferes with what is 
otherwise a natural process. It is crucial to explore the alternatives that mimic the beneficial effects of ERT, especially with regard to the minimization 
of the risk of developing CHD and further evaluation of the aforementioned risks in terms of lipid profiling while simultaneously keeping the health 
risks to a minimum. This review discusses the scope of use of phytoestrogen specifically pertaining to lipid profiling, their possible health benefits, 
and adverse effects if any.
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INTRODUCTION
Estrogen and lipid profile in woman
Menopause is a natural biological phenomenon associated with 
depletion of estradiol production. The decreased estrogen with 
menopause can impact coronary heart disease (CHD) risk factors by 
altering lipoprotein levels [1]. Women in younger age group have a lesser 
risk for cardiovascular events compared with men of their age. Reasons 
for protection from cardiovascular disease in younger women are 
complex; however, a significant contribution of estrogen attributed to 
the greater levels of high-density lipoprotein (HDL) in younger women. 
Moreover, low-density lipoprotein (LDL) and total cholesterol levels 
are low in premenopausal women than same age-matched men [2]. 
This becomes vitally important for women in menopausal transition 
when preventive measures can significantly improve both the quality 
and the quantity of their life. After natural or surgical menopause, the 
total cholesterol and LDL cholesterol (LDL-c) rise [3], HDL cholesterol 
(HDL-c) decreases slightly or may not change [4]. This may be due to 
the loss of estrogen’s protection. Consequently, a number of clinical 
trials have reported that estrogen has a positive effect on lipid levels, 
endothelial cell function, vascular reactivity, and hemostatic factors in 
postmenopausal women. Serum lipid levels are low in women up to the 
age of 50 years as compared with men; however, after menopause, serum 
cholesterol level in women exceeds that of men [5]. Elevated cholesterol 
level accompanied by loss of endogenous estrogen secretion increases 
the risk of developing coronary artery disease in postmenopausal 
women [6]. Population-based studies revealed the beneficial effect of 
hormone replacement therapy in postmenopausal women contrary 
to the cardiovascular disorders [7-9]. The postmenopausal estrogen/
progestin interventions trial revealed that ERT in postmenopausal 
women convincingly showed significant decline in levels of lipoprotein 
(a), LDL, and increased levels of HDL [10].
However, the recent clinical trials such as the heart and estrogen/
progestin replacement study have brought us some unpredicted or even 
surprising findings [11,12]. For example, ERT did not elicit significant 
beneficial effects on cardiac function in women with CHD, thus making 
the clinical application of ERT improve the overall cardiovascular 
health somewhat controversial [11,12]. However, the long-term use of 
estrogen therapy has been found to increase the risk of endometrial 
and breast cancer [13-16]. Hence, the search for efficacious alternative 
strategies is in high demand to resolve the estrogen deficiency-related 
cardiovascular complications in postmenopausal women. Recently, 
attention has been drawn to the value of plant-derived phytoestrogen 
as a potential replacement for estrogen.
PHYTOESTROGENS
Phytoestrogens are polyphenolic non-steroidal naturally occurring 
photochemical substances that are found in foods of plant origin and 
possess a wide range of biochemical benefits which have been found 
to contribute favorably to different health-related problems. They may 
lower LDL-c without inducing hypertriglyceridemia [17,18] and also 
decreases postmenopausal osteoporosis [19], protective effect against 
breast cancer [20], and neuroprotective [21]. These seem to possess 
both estrogenic and anti-estrogenic effects due to their similarity in 
structure to estrogen, the overall effect produced depending on the 
amount of circulating endogenous estrogen, the type of the tissue that it 
binds to, as well as the receptor regulation and perhaps to a little extent 
on the source and class to which the phytoestrogen belongs.
Phytoestrogens consist of more than 20 compounds and could be 
found in over 300 plants [22,23]. There are main three classes of 
phytoestrogens, which include isoflavones, lignans, and coumestans. 
Other phytoestrogens comprise stilbenes, flavonols, flavanones, and 
flavones. Isoflavones are natural non-steroidal molecules with structural 
similarity to 17-β estradiol and selective estrogen receptor modulators. 
Genistein and daidzein are two of the thousands of isoflavones that are 
most extensively investigated as they are thought to possess extremely 
high estrogenic activity. Legumes such as soy, clover, chickpeas, beans, 
and lentils are the rich sources of isoflavones [24]. The lignans were 
commonly present in the plant kingdom, and the lignin was found in 
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the plant cell wall. This is found huge quantities in flaxseed and to a 
little extent in whole grains, beans, lentils, fruits, and vegetables. They 
are thought to possess antitumorigenic and antioxidant properties 
as well [25]. Coumestans are found in mung bean sprouts, spinach, 
sprouts, and brussel. The most important coumestan consumed by 
humans is in the form of coumestrol. Resveratrol and pterostilbene, 
belonging to the family of stilbenes, are commonly found in peanuts 
and red wine. Estrogenic activity is exhibited by resveratrol only in the 
Trans form [26].
ISOFLAVONES
Chemical nature: Polyphenolic compounds with twelve different forms.
Source: Richest in soybeans and soy products.
Biologically active form: Aglycone form.
Animal studies
Soy isolates containing isoflavonic phytoestrogens have favorable 
effects on lipid profiles, without any adverse effect on the reproductive 
system in prepubertal Rhesus monkeys [27]. The US Food and Drug 
Administration approved that “25 g of soy protein a day, as part of a 
diet low in saturated fat and cholesterol, may reduce the risk of heart 
disease” (Food and Drug Administration, 1999). A randomized, double-
blind study carried out by investigators [28] on white male cholesterol-
fed rabbits to check the effects of probiotic bacteria, simvastatin, 
and isoflavones on lipid profile showed that animal groups on a 
hypercholesterolemic diet supplemented with soy isoflavones reduced 
the serum total cholesterol and non-HDL-c concentration albeit this 
reduction was not of much statistical importance in comparison to 
those animal groups that were fed on hypercholesterolemic diets plus 
simvastatin, a cholesterol-lowering drug or even those groups that 
were supplemented with a probiotic microorganism Enterococcus 
faecium CRL 183. Animal experiments have shown that the serum lipid-
lowering properties of soy protein are primarily due to the presence of 
isoflavones [29]. Soy contents of 7S globulin protein possibly upregulate 
LDL receptors and thereby reduce serum LDL concentrations has 
shown by some of the in vitro studies [30]. Zucker rats were fed 
with soy protein enriched with isoflavones for 42 days reduced fatty 
liver and reduced the plasma levels of aspartate transaminase and 
alanine transaminase, increased activities of acetyl-CoA carboxylase, 
mitochondrial and peroxisomal beta-oxidation, fatty acid synthase, 
and glycerol-3-phosphate acyltransferase in liver. These results are 
accompanied by decreased hepatic mRNA level of VLDL receptor and 
increased plasma triacylglycerol level [31].
Human studies
A meta-analysis of 29 articles established that the intake of soy protein 
in humans showed significant improvement in lipid profile [17]. The 
29 articles included 38 clinical trials, of which 34 trials included adult 
subjects and 4 with children as subjects, all of which were analyzed 
independently. The analysis drew a consistent finding that replacement 
of animal protein with soy protein led to a significant reduction in LDL-c 
and serum cholesterol in 34 of the 38 trials; in the 4 trials, did not report 
such conspicuous reductions; the subjects had a properly normal main 
cholesterol values. It was also noted that the variations in the serum lipid 
profile concentrations were independent of changes in body weight, 
dietary intake of cholesterol, total fat, and saturated fat while the factor 
responsible for the variance observed among the studies was the initial 
serum cholesterol concentrations. Randomized, double-blind, placebo-
controlled study to check the effects of soy protein in postmenopausal 
women on lipid profile with mild hypercholesterolemia showed a 
positive effect on lipid levels, i.e., a significant reduction in LDL and 
serum cholesterol levels but also showed that statistically similar 
values can be obtained with a placebo-milk protein [32].
A relatively recent meta-analytical study concerning the effects of 
isoflavonic soy protein on lipid profile of 11 randomized controlled 
trials published from 1990 to 2006 identified by PUBMED concluded 
that isoflavones present in soy protein significantly reduced serum 
total cholesterol, triacylglycerol, and LDL-c, and significantly improved 
HDL cholesterol; however, the changes are associated with duration of 
intake, level, and sex [29]. Studies with intakes >80 mg/day showed 
more favorable effects on lipid profile in comparison to the ones with 
lower intakes. The HDL concentration increase was seen in only those 
subjects where the phytoestrogen intake was continued for over 
12 weeks as opposed to the reductions in LDL, serum total cholesterol, 
and triacylglycerol concentrations which occurred first. As for the 
variations in sex, it was noted that the decline in serum cholesterol, 
LDL-c was seen to a much greater degrees in men than in women. The 
meta-analysis drew conclusions that the initial serum cholesterol level 
played a great role in the effects seen post phytoestrogen intake owing 
to a greater decrease in risk factors in hypercholesterolemic patients 
than in subjects with baseline cholesterol values [33].
The American Heart Association recognizes that eating soy protein can 
help decrease LDL-c levels by two to seven percent [34,35]. In an another 
study, it was reported that soy protein decreased LDL-c levels five to six 
percent [36]. Soy protein may have rendered beneficial effects on lipid 
profile; however, these data are insufficient to conclude that isoflavone 
component, i.e., phytoestrogens, is responsible for the results produced 
as alcohol-extracted soy protein isoflavones without soy protein do not 
affect serum lipid profile in hypercholesterolemic men, indicating that 
isoflavones interacting with other components of soy protein may be 
responsible for the results observed [37]. In 2006, Reynolds et al. by 
a meta-analysis found that significant reduction in triglycerides (TG), 
cholesterol, and LDL and increased HDL levels [38]. A recent study in 
type 2 diabetes mellitus people showed that daily dose of 60 grams soy 
nuts for two months caused a significant reduction in the levels of total 
cholesterol, LDL-c; however, it did not show a significant effect on the 
levels of TG and HDL-c [39].
A very real point of uncertainty is regarding the long-term effects that 
these substances can have on the body. A 2008 clinical report [40] 
showed that data regarding phytoestrogens are not sufficient enough to 
ascertain whether the incorporation of these substances in daily diets 
beyond a certain measure is medically safe. The report documented 
abnormal uterine bleeding with endometrial pathology in three women 
(aged 35-56), all of whom were accustomed to a relatively high intake 
of soy products in their diets. In all three women, it was found that after 
the reduction or elimination of soy product intake, their symptoms 
ameliorated leading to conclusions that long-term consumption of 
phytoestrogens could be harmful. Large intervention trials designated 
that soy protein intake will affect CHD risk immediately after the 
menopause [41]. Recently, few soy interventional studies [42,43] have 
found little or no beneficial effect on serum lipid levels.
Lignans
Chemical nature: Dimeric phenylpropanoids.
Source: Richest in flaxseed (linseed).
Whether the cholesterol-lowering activities of flaxseed is to be 
attributed to one of its components or an interaction between the 
varying components was an issue that needed to be dealt with, for 
flaxseed a rich source of dietary fiber which in itself is an established 
cholesterol-lowering agent [44], is also rich in α-linolenic acid - an ω-3 
fatty acid - A substance thought to bring about a favorable lipid profile 
and also rich in lignans - substances seeming to possess estrogenic 
activities, with insufficient evidence regarding the latter two.
Animal studies
The component present in flaxseed is α-linolenic acid which is 
responsible for the hypocholesterolemic activity. Type II flaxseed 
(CDC-flaxseed) which has similar lignan and oil content but has very 
little α-linolenic acid would have no such effects. A study carried out 
to check the action of CDC-flaxseed/Type II flaxseed on lipid profiles in 
rabbits concluded that the cholesterol-lowering properties of flaxseed 
were independent of the α-linolenic acid component [45]. This could be 
extrapolated to believe that the antiatherogenic properties of flaxseed 
could be attributed to their lignan components though further studies 
are required to unequivocally establish this. A study carried out with 
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flax seed chutney was able to lower the cholesterol levels and shown 
the antioxidant protective effect against the carbon tetrachloride-
induced hepatotoxic damage in rats [46]. To check the effects of linseed 
consumption on lipid profile in rabbits on a hypercholesterolemic diet, 
investigators conducted an experimental study involving a total of 20 
adult male white rabbits that were divided into two groups, a control 
and an experimental group. Both groups were fed on a specific diet 
plus 1% cholesterol from a lyophilized egg throughout the 56-day 
course of the study. In addition, the experimental group was fed ground 
linseed (8 g/kg) from day 29 to 56. The study drew conclusions that 
although there was an elevated level of serum total cholesterol in both 
groups, this increase was highly significant with the control group. Also 
noted was that LDL-c was lower in the group that was supplemented 
with linseed whereas the HDL-c and serum TG showed insignificant 
differences between the two groups [47].
Human studies
A randomized controlled, double-blind parallel study conducted 
to check the efficacy of flaxseed (Type I flaxseed) on lipid profile 
concluded that the supplementation of the diet of postmenopausal 
women with ground whole flaxseed of 40 g, consumed daily for a period 
of 3-month, resulted in decrease of serum levels of both low-density 
and HDL-c by 4.7% and triglyceride concentration by 12.8%, though 
these changes were statistically insignificant, it was rather in contrast 
to the group that was supplemented with a wheat-based comparative 
regimen [48]. The effectiveness of flaxseed and its derivatives on 
serum lipid profiles in adult investigators [49] carried out a meta-
analysis of 28 randomized controlled trials which showed that whole 
flaxseed interventions resulted in significant decrease in LDL and total 
cholesterol, in contrast to flaxseed oil that exerted only a statistically 
insignificant effect perhaps because flaxseed oil lacks dietary fiber and 
lignans. Flaxseed and its products were shown favorable effects on 
those with relatively high primary cholesterol concentrations leading 
to believe that the primary cholesterol levels played a very influential 
role in their action. Also noted was that the hypocholesterolemic effect 
was more pronounced in women than in men, the reasons for which 
remain uncertain and need further evaluation.
Coumestans
Chemical nature: Coumestrol.
Source: Legumes are the main source of coumestrol.
Very few studies have been reported in this area. It was observed that 
ovariectomized rats receive the coumestrol showed the anabolic effect 
on cholesterol in liver [50]. Nogowski et al. reported coumestrol had 
no significant effect on plasma insulin or glucagon concentrations [51]. 
In another study, dietary coumestrol in chicks decreased plasma 
cholesterol concentrations in a dose-dependent manner [52].
Another phytoestrogen-containing dietary hypolipidemic herbal 
product is seeds of fenugreek. Fenugreek seeds are an important 
component of Indian spices that are used regularly in Indian foods. 
Trigonella foenum graecum commonly known as fenugreek belongs 
to the family Fabaceae. The plant contains active constituents such as 
alkaloids, flavonoids, steroids, and saponins [53]. Diosgenin, which 
is used to make synthetic estrogen, is present in Fenugreek seeds. 
In 2014, Kumar et al. stated the hypolipidemic effect of Fenugreek 
seed extract on high--fat diet-induced obese rats [54]. Abedinzade 
et al. in 2015 reported the antihyperlipidemic effect of fenugreek 
seed extract in ovariectomized rats [55]. The steroidal components 
(saponins and sapogenin) present in fenugreek seeds are responsible 
for hypolipidemic effect [56]. Other mechanisms responsible for 
hypolipidemic effect include activation of lecithin-cholesterol acyl 
transferase, lipoprotein lipase, triglyceride lipase, and increased 
excretion of bile acids. Thermostable extract of fenugreek seeds can 
inhibit the fat accumulation in differentiated cells through reduced 
adipogenic factors expression such as peroxisome proliferators 
activated receptor-γ, CAAT element binding proteins-α and sterol 
regulatory element-binding protein-1 [57,58]. In a study, a dose of 
1000 mg/day supplementation of a standardized extract of fenugreek 
to postmenopausal women, showed a significant increase in 
plasma estradiol level and improvement in the quality of life of the 
postmenopausal woman. Biochemical parameters showed positive 
role in the management of lipid profile values [59].
Our pilot data (unpublished) also showed the beneficial effect of 
fenugreek seed extract in ovariectomized rats. After the treatment 
with fenugreek, ovariectomized rats showed decreased cholesterol 
level. These rats also showed better memory and learning after the 
treatment with fenugreek. Presently we are evaluating the role of 
fenugreek seed extract on various inflammatory markers, certain genes 
that are associated with energy storage, lipid metabolism and adipocyte 
differentiation using ovariectomized rat as a menopausal model.
CONCLUSION
The majority of the studies suggest increased phytoestrogen intake 
especially in those subjects with pre-existing hypercholesterolemia 
result in lower serum total cholesterol and LDL levels, and in some cases 
lead to an increase in HDL levels the latter result being achieved only on 
prolonged consumption. The extent of these changes is in proportion to 
intake both quantity and duration, the source and thereby the specific 
type of phytoestrogen consumed. The factor that acts as a modulator of 
these effects produced seems to be the initial blood lipid values. Though 
these results reach statistical significance in most studies considered 
in this review, whether dietary supplementation of phytoestrogens 
can replace the well-established cholesterol lowering agents, statins, is 
probably something that cannot be answered at the moment. Further, 
the small sample sizes, variability in the study designs, various types 
of phytoestrogens used, different doses and duration of treatment 
preventing us from drawing any firm conclusion.
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